Meeting
2022 ASCO Annual Meeting
Open-label, active-control, phase 2/3 study of zilovertamab vedotin plus standard of care in patients with relapsed or refractory diffuse large B-cell lymphoma.
Authors
Patrick Wayne Cobb
St. Vincent Healthcare Cancer Centers of Montana, Billings, MT
Patrick Wayne Cobb , Heng Zhou , Akash Nahar , Patricia Marinello
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT05139017
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS7592)
DOI
10.1200/JCO.2022.40.16_suppl.TPS7592
Abstract #
TPS7592
Poster Bd #
237b
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Phase 3 trial (GCT3013-05) of epcoritamab versus standard of care in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
First Author: Catherine Thieblemont
Poster
2014 ASCO Annual Meeting
Phase 2 open-label study of MEDI-551 and bendamustine versus rituximab and bendamustine in adults with relapsed or refractory CLL.
First Author: Douglas Edward Gladstone
Poster
2023 ASCO Annual Meeting
waveLINE-007: Phase 2 study of zilovertamab vedotin (ZV) in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab (R-CHP) in previously untreated diffuse large B-cell lymphoma (DLBCL).
First Author: David Lavie
Poster
2023 ASCO Annual Meeting
Zilovertamab vedotin (MK 2140) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Early results from the phase 2 waveLINE-004 study.
First Author: Muhit Ozcan